Moleculin Biotech Inc. (MBRX)
1.06
-0.05 (-4.50%)
At close: Apr 25, 2025, 3:59 PM
1.06
-0.47%
After-hours: Apr 25, 2025, 04:21 PM EDT
-4.50% (1D)
| Bid | 1.06 |
| Market Cap | 15.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.76M |
| EPS (ttm) | -6.32 |
| PE Ratio (ttm) | -0.17 |
| Forward PE | -0.62 |
| Analyst | Buy |
| Ask | 1.11 |
| Volume | 245,206 |
| Avg. Volume (20D) | 6,497,805.6 |
| Open | 1.10 |
| Previous Close | 1.11 |
| Day's Range | 1.03 - 1.10 |
| 52-Week Range | 0.40 - 5.47 |
| Beta | 2.20 |
About MBRX
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 17
Stock Exchange NASDAQ
Ticker Symbol MBRX
Website https://www.moleculin.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 463.38% from the latest price.
Stock Forecasts2 months ago
+202.38%
Moleculin Biotech shares are trading higher after ...
Unlock content with
Pro Subscription
4 months ago
+14.72%
Moleculin Biotech shares are trading higher after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model which demonstrated significant activity.
